Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (iparomlimab + tuvonralimab) plus docetaxel in PD-1/PD-L1–resistant lung squamous cell carcinoma
ChiCTR2600122336Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 and docetaxel in Pulmonary squamous cell carcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate (ORR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QL1706docetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2600122336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122336.